Merrimack initiates dosing in MM-111 combination Phase 1 study in advanced HER2 posit
 

Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.

More...